Phosphatidylserine Memory Randomized Trial: What the Evidence Says

Quick Answer

Phosphatidylserine Memory Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Sleep is a complex biological process whose evolutionary purpose has remained equivocal for quite some time.More recently, however, compelling evidence has emerged, leading to recognition of the numerous metabolic and physiological functions sleep contributes to and actively supports. [Conti Federica (2026); evidence level 4]
• Epidemiological studies have revealed that sleep deprivation is associated with an increased risk of all-cause mortality,alongside numerous chronic conditions imposing a heavy burden on our healthcare and socioeconomic systems alike,including cardiovascular disease, stroke, obesity, type 2 diabetes, and various types of cancer and neurological disorders. [Conti Federica (2026); evidence level 4]
• Given the lack of disease-modifying therapies for dementia, interventions that can stabilize or improve cognition at the MCI stage may substantially reduce future dementia incidence and associated healthcare costs. [Oh Kang-Il (2026); evidence level 4]
• Because reduced BDNF signaling is closely linked to synaptic dysfunction and memory decline in MCI, we measured BDNF expression in both in vitro and in vivo experiments and assessed downstream ERK/AKT/CREB signaling in the in vivo model. [Oh Kang-Il (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For phosphatidylserine memory randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Conti Federica (2026). Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. DOI: 10.1093/nutrit/nuaf062. PMCID: PMC13075487. PMID: 40418260. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13075487/
• Oh Kang-Il (2026). Neuroprotective Effect of the Combined Extract of Mentha piperita and Cornus officinalis Against Neuronal Cell Death and Scopolamine-Induced Memory Impairment. DOI: 10.3390/ijms27052508. PMCID: PMC12985713. PMID: 41828723. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12985713/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.